SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound on elevated volume has traders speculating about a news leak or buyout, partly reading CEO Angelos Stergious anniversary message as a signal; neither claim is confirmed. The main underlying focus is the Phase 3 REGAL trials final analysis, triggered at 80 deaths after 78 were last disclosed: bulls interpret the wait as a possible sign of longer survival, while skeptics note the results remain uncertain.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp move is drawing attention as shares push above recent technical resistance, while traders point to anticipated DM1 and FSHD siRNA data as potential catalysts. Some see strength or possible short covering, while others caution that past rallies have faded and no new catalyst is confirmed in the discussion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and raised outlook have been met with a sharp selloff, prompting frustration and debate over why strong demand and guidance have not supported the shares. Traders point to profit-taking and elevated expectations, while cost pressures, weaker cash conversion and an insurance-unit loss have raised questions about margins and the quality of the results.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial

Equity

Greenwich LifeSciences said the delay in filing Form 10-K was due to accounting adjustments tied to stronger-than-expected patient enrollment in its Phase III trial to treat breast cancer.

Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Greenwich LifeSciences from a "hold" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Greenwich LifeSciences in a research report issued on...

Why Did GLSI Stock Rise Pre-Market Today?  

The company unveiled new Phase 3 data suggesting its breast cancer vaccine candidate could work across a broader patient population than initially targeted


Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) will be releasing earnings after the market closes on Tuesday, April 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-21-greenwich-lifesciences-inc-stock...

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) will be releasing earnings after the market closes on Tuesday, March 31. (View Earnings Report at...

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% - Should You Buy?

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% - Time to Buy...

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the target of a significant drop in short interest in January. As of January 30th, there was short interest totaling 1,318,481 shares...

HC Wainwright Issues Positive Forecast for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Greenwich LifeSciences in a report released on...

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The company said the accounting adjustments are not material and do not affect its cash position or business fundamentals.</li><li>As of March 31, 2026, Greenwich reported an unaudited cash balance of approximately $10.5 million.</li><li>The biotech firm is currently conducting the Flamingo-01 trial for GLSI-100 to treat breast cancer, with more than 1,300 patients screened to date.</li></ul>Greenwich LifeSciences (GLSI) drew investor attention on Monday as the biotech company eased concerns over its Nasdaq listing status by providing an update on its delayed Form 10-K filing, offering fresh confidence that the long-awaited report is nearing completion.At the time of writing, <a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> was up more than 7% in pre-market trading.<h2 class="st-heading-2">Form 10-K Filing Delayed Due To Auditors</h2>The company said its 2025 annual report is still under review by its new auditor and is in the final stages of approval. Greenwich attributed the delay to coordination requirements between its current and former auditors, as well as adjustments to accounts payable linked to increased patient screening and enrollment in Europe for its global Phase III study.The company said the accounting adjustments are not material and do not affect its cash position or business fundamentals. As of March 31, 2026, Greenwich reported an unaudited cash balance of approximately $10.5 million.<h2 class="st-heading-2">Nasdaq Compliance Timeline: What Investors Need To Know</h2>April 22, 2026: The firm received a notice from Nasdaq’s Listing Qualifications Department after failing to file its annual Form 10-K for fiscal 2025 by the required deadline.April 30, 2026: The company said its Form 10-K remained under audit as its current and former auditors worked to reach an agreement on the final figures. Greenwich noted that the review involved accounts payable adjustments tied to its ongoing Flamingo Phase III clinical trial and stronger-than-expected patient screening and enrollment across Europe in 2024 and 2025.May 22, 2026: Greenwich received an additional notice from Nasdaq related to the continued delay in filing its Form 10-K.Greenwich LifeSciences is currently conducting the Flamingo-01 trial for GLSI-100 to treat breast cancer, with more than 1,300 patients screened to date.Preliminary data have shown an estimated 70% to 80% reduction in breast cancer recurrence rates after the initial six-dose treatment series. The company also reported a significant increase in immune responses among treated patients.<h2 class="st-heading-2">GLSI Traders Shifts Focus To Breast Cancer Trial</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes. GLSI was also among the top trending tickers on the platform at the time of writing.One user simply said, “Let’s focus on the trial and science again now.”<stembedurl>https://stocktwits.com/WolfSK/message/654939841</stembedurl>Another user called the news a “great update” and the stock should reclaim the $29 - $30 levels today.<stembedurl>https://stocktwits.com/Jack_Danielss/message/654938831</stembedurl>The stock has gained nearly 24% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-repl-stock-gaining-in-pre-market-today/cZ0go7uReH9">Why Is REPL Stock Gaining In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. MRAM and HPAI stocks surged in overnight trading (Image source: Getty Images)

Greenwich LifeSciences (GLSI) drew investor attention on Monday as the biotech company eased concerns over its Nasdaq listing status by providing an update on its delayed Form 10-K filing, offering fresh confidence that the long-awaited report is nearing 

What’s Driving GLSI Stock Today?

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$16.18
Prev Close	$15.21
Open	$15.15
Dividend Yield	0.00%
50-Day Moving Average	$16.65
Beta	1.72
Avg. Volume	112,470.59
PE Ratio	-10.03

52-Week High	$34.10
52-Week Low	$7.78
Market Capitalization	$223.26M
EPS (Annual)	-$1.43
Price to Book	71.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GLSI Fundamentals